SEC Form 4 · accession 0001019687-16-005750
GT Biopharma, Inc. · GTBP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
BRISTOL INVESTMENT FUND LTD
10% Owner
Period of report
Apr 4, 2016
Accepted (ET)
Apr 5, 2016 · 6:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000109657
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 4, 2016 | S | 675,000 | $303,750.00 | D | 1,525,472 | D | |
| Common StockF2 | Apr 5, 2016 | J | 250,000 | — | A | 463,806 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares were sold by Bristol Investment Fund, Ltd., a Cayman Islands exempted company ("Bristol Investment") in a private transaction. Bristol Investment is managed by Bristol Capital Advisors LLC, a Delaware limited liability company ("BCA"). Paul Kessler, as manager of BCA, has voting and dispositive power over the shares beneficially owned by Bristol Investment. Bristol Investment owns a total of 1,525,472 shares of the Company's common stock.
- F2These shares were acquired by Bristol Capital, LLC, a Delaware limited liability company ("BC"), pursuant to an Amendment to Consulting Agreement, for services rendered by BC to the Issuer. BC's principal offices are located at 1100 Glendon Ave., Suite 850, Los Angeles, CA 90024. Paul Kessler, as manager of BC, has voting and dispositive power over the shares beneficially owned by BC.